Current issue #23, 2017

18.07.2017

PharmVestnik # 23, 18/07/2017

Two Erkapharm + three ROSTA pharmacy chains to merge

Consolidation in the pharma retail segment saw a large deal as ROSTA Group sold its pharmacy business to Erkapharm. The merger started immediately after the sale was agreed upon, although the deal itself would close by the end of the year. The united pharmacy chain will be an absolute leader in St. Petersburg, and is likely to make its way to the TOP3 federal chains. Experts note that if Erkapharm team works diligently, the company may evolve as the second largest pharmacy chain in Russia. The question of ROSTA Group’s future remains open. Will the company continue selling out its assets or work out a new strategy?

[PharmVestnik # 23, 18/07/2017, p. 1, cont’d p. 5]

Insurers willing to service direct contracts between manufacturers and pharmacies

Insurance of trade credits has become a common service for pharma companies operating in the Russian market. To date, these were mainly manufacturers insuring payments related to product shipments to distributors. Recently, pharmacies have started purchasing directly from manufacturers, too. There is a limited number of such customers, but insurance companies do not object against them. The only conditions are transparency of operations, and access to information.

[PharmVestnik # 23, 18/07/2017, p. 2]

EAEU authorities not entitled to reject NDAs drafted to union’s regulations

Until December 31, 2025, manufacturers should bring their new drug applications (NDAs) in line with the EAEU regulations. There was enough time for drilling them as it took long to approve the relevant documents. May 6, 2017, was the starting point for the EAEU common market. However, none of pharma companies has filed its NDA in accordance with the new regulations so far.

[PharmVestnik # 23, 18/07/2017, p. 3]

Advances of palliative care arrangement discussed in Moscow

Sixty percent of opioid analgesics manufactured in Russia are used by Moscow medical and preventive institutions (MPIs) as well as palliative care centers for incurable disease patients. According to expert estimations, 56 thousand people in Moscow need palliative care. Currently, about 70% of patients die at hospitals, and 30% — at home. Such data was provided on July 3 by the speakers of the joint meeting of health and social policy committees of Moscow City Duma. Deputies, physicians, MPI heads, health officials, and lead experts of Moscow Health Department discussed palliative care issues in Moscow.

[PharmVestnik # 23, 18/07/2017, p. 10]

Russian cancer care system needs common standards

In late June, it transpired that in 37 Russia’s regions, expenditures associated with purchasing drugs for cancer patients decreased. According to the Research Institute of Healthcare and Medical Management, state funding changes were most obvious in Sakhalin region (-48.5%), Khanty-Mansi autonomous area (-47.9%), and Magadan region (-39%). The experts surveyed insist that this country needs common palliative care standards.

[PharmVestnik # 23, 18/07/2017, p. 11]

Foreign companies to encourage Russian R&D

R&D localization is not widespread in the Russian pharma market yet. International pharma companies take an interest in Russian scientists; however, most R&D projects boil down to sharing experiences, and building contacts with Russian researchers. However, new working formats have emerged recently.

[PharmVestnik # 23, 18/07/2017, p. 12]

Tests by independent Czech lab confirmed tadalafil content in Erectogenon

The issue of manufacturing and selling counterfeit erectile dysfunction supplements has been brought up for many years, but until recently the discussion was confined to restricted professionals. However, it looks like the situation is changing. Supposedly, the documentary film investigating the issue that was recently run on TV would not only fall under public scrutiny but would also give fresh impetus to court proceedings.

[PharmVestnik # 23, 18/07/2017, p. 12]

Replication of foreign technologies will not help Russian medical industry

On June 29—30, Moscow Expocenter fairgrounds hosted the 1st Eurasian Orthopedic Forum visited by about 3,000 delegates, including doctors, officials, and medical manufacturers from 65 countries representing Eurasia, Australia, North America, and Africa. During the roundtable discussion initiated by the Ministry of Industry and Trade, some medical experts criticized local medical products for their quality stating that the demand for them was lower than for similar products imported. At the same time, experts acknowledge that the development of local manufacturing facilities is impossible without entering foreign markets. But replication of the best foreign technologies is unlikely to help. The participants of the roundtable on medical manufacture and export explained why.

[PharmVestnik # 23, 18/07/2017, p. 17]

MoH not to support development of separate regulation on medical device circulation

The bill “On medical device circulation” has been revised and updated for 5 years. None of the revisions has been submitted for a State Duma review. An attempt at making a law similar to that regulating drug circulation failed in 2014. Since that time, the professional community has been coming back to discussing this bill every year.

[PharmVestnik # 23, 18/07/2017, p. 18]

Specifics of medical device procurement in Russia

Over the past year, a new approach to controlling medical device procurement via government biddings has taken shape. According to experts, supervisory authorities closely monitor the procurement item description, namely, the number of components in a medical device specification.

[PharmVestnik # 23, 18/07/2017, p. 18]

Analysis of government procurement of coronary stents, Q116—Q117

Coronary stent purchases in Q117 decreased by 2% in value terms; absolute expenditures fell by 38 m RUB. An average per item price went down by nearly 10%, whereas an average foreign currency rate fell by 20%. A relative purchase stability and lowering per item price may be explained by ruble strengthening and a growing share of manufacture localized in Russia.

[PharmVestnik # 23, 18/07/2017, p. 19]

Sales review of drugs for lower extremity varicose veins on Russian pharma market, May 2016 — April 2017 (МАТ 04/2017)

In summer when hot weather increases the total body load, including foot vessels, venous flood flow may be hampered, and venous hyperemia in the lower extremities may form. In this period, an upsurge of varicose vein drug sales is observed. In Russia, more than 30 m people suffer from various forms of varicosis. A high disease prevalence drives the development of the varicose vein drug market.

[PharmVestnik # 23, 18/07/2017, pp. 22-23]

Review of systemic antihistamine segment in Russia, January—May 2017

In summer, the demand for systemic antihistamine drugs traditionally goes up. One of the causes is blossoming; pollen induces exacerbation of vasomotor rhinitis in allergy-prone people. The cold spring 2017 has not affected systemic antihistamine sales. It looks like this group sales dynamics depends on customer purchasing capacity, not on allergen counts in the air.

[PharmVestnik # 23, 18/07/2017, pp. 26-27]

Russian and localized foreign companies go export

Export potential development is a current trend and a new import substitution stage. Going beyond borders was one of major topics on the agenda of the International Economic Forum in St. Petersburg – and not only theoretically. E.g., Sanofi announced the start of exporting insulins manufactured at its facility in Oryol region to the EU, which means that not only Russian but also localized foreign companies export their products. But are the concepts of export equivalent in these two cases?

[PharmVestnik # 23, 18/07/2017, p. 28]

Effective cancer drugs not readily appear on restrictive lists

The rules of entering news drugs into restrictive lists are often violated, these rules being far from optimal themselves. This issue was on the agenda of the discussion on health economics in oncology within the framework of the 3rd International Forum “Northern Summer Nights St. Petersburg”.

[PharmVestnik # 23, 18/07/2017, p. 29]

Herbal drug manufacturer relies on growing raw materials inhouse

Pursuant to the HealthNet roadmap of the National Technological Initiative, herbal API and drug exports must be not less than 1 m tons by 2035. Driven by state priorities, Anapa-based Phytopharm launched a pilot project on growing and processing mint and motherwort in ecologically clean Caucasus piedmont area. Presently, the company purchases 90% of herbal raw materials from vendors. It plans to decrease this share to 50%.

[PharmVestnik # 23, 18/07/2017, p. 29]

Biotech investment projects stalled in Southern Russia

A biotech cluster is to be created in Rostov to manufacture APIs. The project initiated by Research and Production Center Bioproducts was to be implemented three years ago; however, the investor encountered problems at the site selection stage. Quite recently, the investor chose the location for the facility, registered it under its ownership, and asserts that the facility would be put into operation in 2019. The funding sources and amount have not been disclosed.

[PharmVestnik # 23, 18/07/2017, p. 30]

Ural economy grows due to medical grade glass production

After a three-year break, Japanese Nipro Corporation resumed funding of Ural glass plant (Sverdlovsk region) manufacturing ampoules, vials, and cartridges for pharmaceutical facilities. The plant plans to boost sales due to Asian and African markets.

[PharmVestnik # 23, 18/07/2017, p. 30]

Регистрируясь, вы принимаете условия
Пользовательского соглашения